Discovery and clinical introduction of first-in-class imipridone ONC201

Author:

Allen Joshua E.1,Kline C. Leah B.2,Prabhu Varun V.1,Wagner Jessica2,Ishizawa Jo3,Madhukar Neel4,Lev Avital2,Baumeister Marie2,Zhou Lanlan2,Lulla Amriti2,Stogniew Martin1,Schalop Lee1,Benes Cyril56,Kaufman Howard L.7,Pottorf Richard S.8,Nallaganchu B. Rao8,Olson Gary L.8,Al-Mulla Fahd9,Duvic Madeleine3,Wu Gen Sheng10,Dicker David T.2,Talekar Mala K.11,Lim Bora3,Elemento Olivier4,Oster Wolfgang1,Bertino Joseph7,Flaherty Keith56,Wang Michael L.3,Borthakur Gautam3,Andreeff Michael3,Stein Mark7,El-Deiry Wafik S.2

Affiliation:

1. Oncoceutics, Inc., Philadelphia, PA, USA

2. Fox Chase Cancer Center, Philadelphia, PA, USA

3. University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Weill Cornell Medicine, New York, NY, USA

5. Massachusetts General Hospital, Boston, MA, USA

6. Harvard Medical School, Boston, MA, USA

7. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

8. Provid Pharmaceuticals, Monmouth Junction, NJ, USA

9. Kuwait University Medical School, Kuwait

10. Karmanos Cancer Institute, Detroit, MI, USA

11. The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3